Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
18 Years
89 Years
Both
Glioblastoma Multiforme, Controls (Those Without Glioblastoma Multiforme)
Trial Information
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are
increasingly recognized for occasionally metastasizing through the peripheral blood to
distant locations. This research study involves the detection and novel characterization of
human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor
patients by identifying their unique cell surface antigen profile, determining an optimal
isolation protocol, and quantitatively and qualitatively reporting the yield and
characteristics.
Inclusion Criteria:
- 18 to 89 years of age
- Weight of at least 110 pounds
- Able to provide informed consent for self
Exclusion Criteria:
- Patients with active malignant tumors other than GBM
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Identification of Human GBM CD Antigen Signature.
Outcome Description:
Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.
Outcome Time Frame:
3 Years
Safety Issue:
No
Principal Investigator
Erin M Dunbar, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Florida
Authority:
United States: Institutional Review Board
Study ID:
CTC-01
NCT ID:
NCT01135875
Start Date:
October 2009
Completion Date:
August 2013
Related Keywords:
- Glioblastoma Multiforme
- Controls (Those Without Glioblastoma Multiforme)
- GBM
- Brain Tumor
- Brain Neoplasm
- Control
- Normal Control
- Volunteer
- Glioblastoma
Name | Location |
|---|---|
| University of Florida | Gainesville, Florida 32610-0277 |
